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A B S T R A C T
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin
and inhibiting leukocyte migration to the central nervous system. We recently reported an association between
low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing
interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of
the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35)
fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated
with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to
establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms.
1. Introduction
Natalizumab (Tysabri®, Biogen) administered intravenously at a
standard dose of 300 mg every 4 weeks efficiently reduces disease ac-
tivity in relapsing-remitting multiple sclerosis (RRMS) [1]. By blocking
α4 integrin on leukocytes, natalizumab inhibits leukocyte adhesion to
and migration over the blood-brain barrier. Natalizumab receptor oc-
cupancy (RO) refers to the proportion of α4 integrins occupied by na-
talizumab on single cells, and has been suggested as a biomarker to
monitor therapeutic efficacy and possibly patient-tailor therapy [2].
Neurofilament light chain (NF-L) is another emerging biomarker for
disease activity and neuroaxonal damage in RRMS, and is reported to
return to levels of healthy individuals following initiation of natali-
zumab therapy [3].
Approximately 50% of patients treated with natalizumab report a
feeling of the effect “wearing off” towards the end of the 4-week dosing
interval, and that subjective symptoms, most commonly fatigue, in-
crease during the last week of the dosing interval and improve shortly
after receiving the next infusion [4–6]. The underlying mechanisms of
this phenomenon are unknown, but we recently found that patients
who regularly reported wearing-off symptoms at the end of dosing in-
tervals had lower natalizumab RO than those reporting such symptoms
occasionally or never [6]. Here, we aimed to investigate if the patients
who regularly reported wearing-off symptoms had increased risk of
disease activity during a 1-year follow-up.
2. Methods
2.1. Subjects
We invited all patients with a diagnosis of RRMS over 18 years of
age who had received a minimum of six natalizumab infusions at the
Department of Neurology, Haukeland University Hospital (n = 45) to
participate, of whom 40 (88.9%) participated after written informed
consent. The study was approved by the Regional Ethics Committee
(REK 2016/579).
2.2. Evaluation at inclusion and after one year
At inclusion, we obtained baseline demographic and clinical data
including MRI lesion activity and clinical relapses in the last year prior
to inclusion from the patient's medical journal. Each patient filled in
questionnaires on fatigue (Fatigue Severity Scale; FSS) [7], and on
working status, smoking habits, weight, height, and whether they had
wearing-off symptoms regularly (at the end of every dosing interval),
sometimes (at the end of some dosing intervals), or never. A trained
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neurologist evaluated disability levels by the Expanded Disability Status
Scale (EDSS) and cognitive function was assessed by the Symbol Digit
Modalities Test (SDMT) [8] at inclusion and after one year. In addition,
the first registered SDMT score, assessed when each patient received
their first natalizumab infusion at our department, was obtained from
the medical journal. MRI was conducted at inclusion and after one year
and clinical relapses were registered during the 1-year prospective
follow-up. No evidence of disease activity (NEDA) was defined as
freedom of relapses and EDSS worsening, and lack of new or enlarged
T2 lesions on MRI. Serum collected at inclusion and after one year was
stored at −80 °C and NF-L was quantified with a single-molecule array
(Simoa) assay (Quanterix).
2.3. Statistical analysis
For statistical analysis, patients were separated into two groups
based on whether they reported wearing-off symptoms regularly (at the
end of every dosing interval) or not (only sometimes or never). Patient
characteristics, clinical and radiological signs of disease activity, and
NF-L levels at baseline and after a 1-year follow-up were compared
between the groups using a Kruskal-Wallis test. Statistical differences
with p < .05 were considered significant using a two-sided compar-
ison. Holm's method was used to adjust for multiple comparisons.
3. Results
Table 1 shows patient characteristics at inclusion and after a 1-year
follow-up. After one year, five of the 40 included patients no longer
received natalizumab therapy at our hospital; one had moved to an-
other region and four had switched to other therapies due to antibodies
against JC virus (n= 2), side effects of natalizumab (n= 1), or planned
pregnancy (n = 1). None of these five patients had reported wearing-off
symptoms regularly at inclusion.
None of the 35 remaining patients experienced clinical relapses,
new or enlarged T2 lesions on MRI or EDSS score changes of> 1 point
during the 1-year follow-up period. Thus, all remaining patients ful-
filled the criteria for NEDA.
At inclusion, patients reporting regular wearing-off symptoms had
higher BMI and higher frequency of sick-leave than patients with
wearing-off symptoms only sometimes or never [6]. None of the pa-
tients had experienced clinical relapses or new or enlarged MRI lesions
in the year prior to inclusion in the study. Median EDSS was similar
between the wearing-off groups both at baseline and after one year.
Patients reporting wearing-off regularly had poorer median FSS (higher
score) and SDMT (lower score) than patients reporting symptoms only
sometimes or never both at inclusion and after one year, and these
differences became statistically significant after 1-year follow-up.
However, none of the differences were statistically significant after
adjusting for multiple comparisons. SDMT scores from the time of the
first natalizumab infusion at our department (at initiation of natali-
zumab therapy for all but two patients) was similar between wearing-
off groups. NF-L levels in serum were similar between the groups at
inclusion and after 1-year follow-up.
Table 1
Patient characteristics at inclusion and after a 1-year follow-up.
Total Wearing-off symptoms p padj
Regularly Not regularly
RRMS patients, n (%)
Baseline 40 (100) 8 (20) 32 (80)
After 1 year 35 (87,5%) 8 (23) 27 (77)
Patient characteristics at inclusion
Age, y 43.0 (34.0–49.3) 43 (37–43.75) 44 (33.5–51) 0.531 1.000
Sex, females, n (%) 25 (62.5) 7 (87.5) 18 (51) 0.107 1.000
BMI 25.3 (22.6–27.2) 27.8 (26.5–31.2) 24.30 (22.34–26.11) 0.008 0.136
Current smoker, n (%) 7 (17.5) 1 (12.5) 6 (18.8) 0.681 1.000
Sick-leave, n (%) 9 (22.5) 4 (50.0) 5 (15.6) 0.040 0.600
Disease duration, y 13.0 (8.0–17.0) 12.5 (8.8–16.0) 13 (8–17.25) 0.747 1.000
Treatment duration, y 4.0 (3.0–7.3) 4.5 (2.0–8.0) 4 (3–7.25) 0.959 1.000
Dose number 56.5 (39.0–102.3) 63.5 (33.5–111.8) 56.5 (39–95.5) 0.933 1.000
Days since last dose 28.0 (28.0–28.0) 28.00 (27.0–28.0) 28 (28–28) 0.382 1.000
Markers of disease activity
New or enlarged MRI T2 lesions
Last year prior to inclusion 0 0 0 – –
During 1-year follow-up 0 0 0 – –
Clinical relapses
Last year prior to inclusion 0 0 0 – –
During 1-year follow-up 0 0 0 – –
EDSS
At inclusion 2 (1.375–3.5) 2 (1.5–2.75) 2 (1–3.5) 0.681 1.000
After 1 year 2 (1.5–3.5) 2 (1.88–2.38) 2 (1–3.5) 1.000 1.000
FSS
At inclusion 4.78 (3.33–5.67) 5.33 (4.83–5.78) 4.44 (3.25–5.67) 0.119 1.000
After 1 year 4.89 (3.56–5.72) 5.89 (5.31–6.31) 4.11 (3.39–5.39) 0.005 0.090
SDMT
At first natalizumab dose 53 (44.5–60.25) 51 (39.5–60.5) 53 (46.5–59.5) 0.672 1.000
At inclusion 57 (50–67.25) 48.5 (45.5–56) 58 (52.75–68.25) 0.052 0.728
After 1 year 59 (50.5–69) 48.5 (47–55.75) 62 (56–70) 0.023 0.368
S-NF-L pg/ml
At inclusion 7.09 (5.27–9.38) 5.19 (5.03–6.09) 7.12 (5.55–9.64) 0.098 1.000
After 1 year 7.71 (5.57–10.82) 6.46 (5.89–7.89) 8.02 (5.45–11.59) 0.610 1.000
Patients reporting wearing-off symptoms at the end of natalizumab dosing intervals regularly (every dosing interval) or not (only sometimes or never).
RRMS= relapsing-remitting multiple sclerosis, EDSS = Expanded Disability Status Scale, FSS = Fatigue Severity Scale, SDMT= Symbol Digit Modalities Test. S-NF-
L = serum neurofilament light chain. P values of independent samples t-test. Padj values are adjusted for multiple comparisons using Holm's test.
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4. Discussion
Subjective wearing-off symptoms at the end of the 4-week dosing
interval are frequent among patients receiving natalizumab infusions,
but the phenomenon remains poorly understood. Recently, we reported
lower natalizumab RO in patients experiencing wearing-off symptoms
regularly, possibly caused by high BMI [6]. In this study, we aimed to
evaluate the risk of disease activity in a 1-year prospective follow-up of
the same patient cohort.
We found that all patients available for follow-up after one year
fulfilled the criteria for NEDA, and that subjective wearing-off symp-
toms were not associated with increased short-term risk of clinical or
radiological signs of disease activity. The similar baseline and 1-year
serum NF-L levels between the patient groups further supported this.
Nevertheless, the small patient cohort and short follow-up in our study
could limit its ability to reveal possible differences in therapeutic effect.
Our patient cohort had a median disease duration of 13 years and had
received natalizumab therapy for median 4 years, which could indicate
that they were a selected group of stable patients. The risk of disease
activity may differ in patients with shorter disease and therapy dura-
tion. Wearing-off symptoms were not associated with cessation of na-
talizumab therapy.
Patients reporting wearing-off regularly had more severe fatigue
and cognitive impairment than patients with symptoms only sometimes
or never. MS-related fatigue and cognitive impairment are common and
affect quality of life independently of physical disability, and the cur-
rent criteria for NEDA have been criticized for not emphasizing fatigue
and cognitive function in the evaluation of therapeutic efficacy [9].
Natalizumab has positive effects on fatigue and cognitive function [10]
and more severe symptoms in the patient group with wearing-off reg-
ularly could thus represent a sub-optimal therapeutic effect. However,
the differences in FSS and SDMT were small and need to be confirmed
in larger populations. SDMT scores were similar between the two
groups at initiation of natalizumab therapy. We have no pre-treatment
FSS scores and can therefore not exclude that differences in fatigue
existed already before initiation of natalizumab therapy.
In conclusion, although regular subjective wearing-off symptoms
are associated with lower natalizumab RO [6], they were not associated
with increased short-term risk of breakthrough disease. Patients with
wearing-off symptoms regularly had more severe fatigue and cognitive
impairment in the 1-year follow-up. The results provide some reassur-
ance that the presence of the wearing-off phenomenon is not associated
with reduced efficacy of the drug. However, longer prospective follow-
up of a larger patient cohort is necessary to determine whether the
therapeutic efficacy of natalizumab is maintained over time in patients
reporting wearing-off symptoms regularly. The characteristics and
clinical significance of the wearing-off phenomenon should be eval-
uated in future randomized studies of natalizumab using different
dosing intervals.
Declaration of Competing Interest
The authors declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: C.A.V. and S.G. have nothing to disclose. G.H.B. has received
research support from Novartis. K.M.M. has received grants and per-
sonal fees from Biogen and Novartis; personal fees from Genzyme,
Roche, Almirall, and Merck; and personal fees and nonfinancial support
from Teva.
Acknowledgements
We thank Fritz og Ingrid Nilsens legat for financial research support,
and Hanne Linda Nakkestad at the Neurological Research Laboratory at
Haukeland University Hospital for performing SiMOA analyses. The
mass cytometry was performed at the Flow Cytometry Core Facility,
Department of Clinical Science, University of Bergen. The Helios mass
cytometer was funded by Bergen Research Foundation. Neuro-SysMed
is jointly hosted by Haukeland University Hospital and University of
Bergen and supported as a Centre for Clinical Treatment Research (FKB)
by grants from The Research Council of Norway, project number
288164.
References
[1] C.H. Polman, P.W. O’Connor, E. Havrdova, et al., A randomized, placebo-controlled
trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med. 354 (2006)
899–910 2006/03/03 https://doi.org/10.1056/NEJMoa044397.
[2] J. Punet-Ortiz, J.V. Hervas-Garcia, A. Teniente-Serra, et al., Monitoring CD49d
receptor occupancy: A method to optimize and personalize natalizumab therapy in
multiple sclerosis patients, Cytometry B Clin. Cytom. (2017), https://doi.org/10.
1002/cyto.b.21527 2017/04/06.
[3] M. Gunnarsson, C. Malmestrom, M. Axelsson, et al., Axonal damage in relapsing
multiple sclerosis is markedly reduced by natalizumab, Ann. Neurol. 69 (2011)
83–89 2011/02/01 https://doi.org/10.1002/ana.22247.
[4] J.N. Ratchford, R. Brock-Simmons, A. Augsburger, et al., Multiple sclerosis
symptom recrudescence at the end of the natalizumab dosing cycle, Int. J. MS Care
16 (2014) 92–98 2014/07/26 https://doi.org/10.7224/1537-2073.2013-017.
[5] Z.L.E. van Kempen, D. Doesburg, I. Dekker, et al., The natalizumab wearing-off
effect: End of natalizumab cycle; recurrence of MS symptoms, Neurology (2019),
https://doi.org/10.1212/WNL.0000000000008357 2019/09/26.
[6] G.H. Bringeland, N. Blaser, K.M. Myhr, et al., Wearing-off at the end of natalizumab
dosing intervals is associated with low receptor occupancy, Neurol. Neuroimmunol.
Neuroinflamm. 7 (2020), https://doi.org/10.1212/NXI.0000000000000678 2020/
02/06.
[7] L.B. Krupp, LaRocca NG, J. Muir-Nash, et al., The fatigue severity scale. Application
to patients with multiple sclerosis and systemic lupus erythematosus, Arch. Neurol.
46 (1989) 1121–1123 1989/10/01 https://doi.org/10.1001/archneur.1989.
00520460115022.
[8] A. Smith, Symbol digit modalities test: Manual, Los Angeles, CA, Western
Psychological Services, 1982.
[9] M. Stangel, I.K. Penner, B.A. Kallmann, et al., Towards the implementation of ‘no
evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis
decision model, Ther. Adv. Neurol. Disord. 8 (2015) 3–13 2015/01/15 https://doi.
org/10.1177/1756285614560733.
[10] P. Iaffaldano, R.G. Viterbo, D. Paolicelli, et al., Impact of natalizumab on cognitive
performances and fatigue in relapsing multiple sclerosis: a prospective, open-label,
two years observational study, PLoS One 7 (2012) e358432012/05/05 https://doi.
org/10.1371/journal.pone.0035843.
G.H. Bringeland, et al. Journal of the Neurological Sciences 415 (2020) 116880
3
